Medical Letter on the CDC & FDA

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Rhabdomyolysis



Studies from Food & Drug Administration update current data on rhabdomyolysis



May 18th, 2008

According to a study from the United States, " To estimate the extent of reporting to FDA through statin-associated rhabdomyolysis data. Data included incidence rates (IRs) of hospitalized rhabdomyolysis among statin users from a population-based study, and comparable reported AERS cases and national estimates of statin use from an AERS analysis."

"Using IRs, national estimates of statin use and average days supply per prescription, we estimated the number of US statin-associated cases of hospitalized rhabdomyolysis. We compared this estimate to the observed number of cases reported to FDA to evaluate the extent of reporting. We repeated this method for atorvastatin,...


Source: Medical Letter on the CDC & FDA (2008-05-18)